The PM-JAY health insurance scheme, launched in India in 2018, was a crucial step towards universal health coverage (UHC). The policy’s design was shaped by a mix of technical and political elements, with a focus on bureaucratic aspects rather than ideological ones. The scheme was introduced by the ruling government just before national elections, leveraging policy legacies from previous and state insurance schemes. Key decisions such as the coverage amount and portability of benefits were centrally driven, while inputs from Indian states influenced features like the mode of implementation and provider network. This balanced approach facilitated the adoption of the reform. However, the scheme’s success hinges on addressing systemic issues and involving all stakeholders. As PM-JAY continues to be implemented, understanding the politics, power dynamics, and structural issues that shaped its formulation will be crucial.
🚀 The FDA has made a groundbreaking move by approving Opdivo (nivolumab) as a neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). This new regimen, combining Opdivo with platinum-doublet chemotherapy, aims to enhance patient outcomes pre- and post-surgery. With promising results from recent clinical trials, it’s a significant step forward in cancer care!
Learn more about this advancement and its implications for patients.
#SyenzaNews #CancerCare #FDAApproval
🌍🧠 Today, on World Mental Health Day, let’s focus on the mental well-being of our youth. With one in seven adolescents experiencing mental disorders, it’s crucial to address the challenges they face in accessing care. Innovative solutions like telemedicine and school-based programmes offer hope.
Let’s advocate for policies that prioritise youth mental health. Together, we can create a supportive environment for young people to thrive. 🌟
#SyenzaNews #WorldMentalHealthDay #YouthMentalHealth #MentalHealthAwareness
🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024.
Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare.
#SyenzaNews #BreastCancer #HealthcareInnovation
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
